<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01214850</url>
  </required_header>
  <id_info>
    <org_study_id>V72_29</org_study_id>
    <nct_id>NCT01214850</nct_id>
  </id_info>
  <brief_title>Novartis Vaccine and Diagnostics Carriage Trial</brief_title>
  <official_title>A Phase 3 Observer Blind Randomized, Multi-center, Controlled Study to Evaluate the Effect of Novartis Vaccine's Meningococcal B Recombinant and MenACWY Conjugate Vaccines on Pharyngeal Carriage of N. Meningitidis in Young Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this trial was to evaluate the effect of Novartis Vaccine's Meningococcal
      vaccines on carriage of Neisseria meningitidis in a young adult population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentages of Subjects With Carriage of Virulent Sequence Types (ST) of Neisseria Meningitidis Group B, One Month After Completion of rMenB+OMV NZ Vaccination</measure>
    <time_frame>61 days (31 days after receiving the second injection)</time_frame>
    <description>Percentages of subjects with carriage of virulent sequence types (ST) of Neisseria meningitidis group B, one month after completion of rMenB+OMV NZ vaccination. The carriage rate of virulent sequence types (ST) of N. meningitidis group B (genogroupable) in subjects, one month after receiving two doses of rMenB+OMV NZ, as compared to the control group, was reported.
Virulent ST types are defined as Clonal Complex multi locus sequence typing (MLST) or ST type being the same compared to history data (Clonal Complexes MLST or ST types found to be virulent and causing diseases) from the years 2006 to 2010.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of Subjects With Combined Carriage of N. Meningitidis Serogroups A, C, W and Y, One Month After MenACWY-CRM Vaccination</measure>
    <time_frame>31 days after MenACWY-CRM injection</time_frame>
    <description>The percentage of subjects with combined carriage rate of N. meningitidis serogroups A, C, W and Y in subjects, one month after receiving a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Carriage of All ST Types of N. Meningitidis B (Genogroupable) at Different Time Points Following rMenB+OMV NZ Vaccination</measure>
    <time_frame>Up to 361 days after vaccination</time_frame>
    <description>The percentage of subjects with carriage of all (virulent + non-virulent) ST types of N. meningitidis B (genogroupable) in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Carriage of Virulent ST Types of N. Meningitidis Group B at Any Time Point After rMenB+OMV NZ Vaccination</measure>
    <time_frame>Up to 361 days after vaccination</time_frame>
    <description>Percentage of subjects with carriage of virulent ST types of N. meningitidis group B (genogroupable) in subjects at different time points of the study point after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Carriage of Nonvirulent ST Types of N. Meningitidis Group B at Any Time Point After rMenB+OMV NZ Vaccination</measure>
    <time_frame>Up to 361 days after vaccination</time_frame>
    <description>Percentage of subjects with carriage of nonvirulent ST types of N. meningitidis group B (genogroupable) in subjects at different time points of the study point after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Carriage of All N.Meningitidis Strain at Different Time Points After rMenB+OMV NZ Vaccination</measure>
    <time_frame>Up to 361 days after vaccination</time_frame>
    <description>Percentage of subjects with carriage of all N.meningitidis strains combined in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Carriage of N.Meningitidis ABCWY Genogroups at Different Time Points After rMenB+OMV NZ Vaccination</measure>
    <time_frame>Up to 361 days after vaccination</time_frame>
    <description>Percentages of subjects with carriage of N.meningitidis ABCWY genogroups in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Carriage of N.Meningitidis ACWY Genogroups at Different Time Points After rMenB+OMV NZ Vaccination</measure>
    <time_frame>Up to 361 days after vaccination</time_frame>
    <description>Percentages of subjects with carriage of N.meningitidis ACWY genogroups in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Carriage of N.Meningitidis Serogroups A,C,W or Y at Different Time Points After rMenB+OMV NZ Vaccination</measure>
    <time_frame>Up to 361 days after vaccination</time_frame>
    <description>Percentages of subjects with carriage of N.meningitidis serogroups A,C,W or Y in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Carriage of N.Meningitidis Genogroup Y at Different Time Points After rMenB+OMV NZ Vaccination</measure>
    <time_frame>Up to 361 days after vaccination</time_frame>
    <description>Percentages of subjects with carriage of N.meningitidis genogroup Y in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Carriage of N.Meningitidis Serogroup Y at Different Time Points After rMenB+OMV NZ Vaccination</measure>
    <time_frame>Up to 361 days after vaccination</time_frame>
    <description>Percentages of subjects with carriage of N.meningitidis serogroup Y in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subject With Carriage of N. Meningitidis Genogroups ACWY at Different Time Points After MenACWY-CRM Vaccination</measure>
    <time_frame>Up to 361 days after vaccination</time_frame>
    <description>Percentages of subject with carriage of N. meningitidis genogroups ACWY in subjects at different time points of the study after administration of a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Carriage of N. Meningitidis Serogroups ACWY at Different Time Points After MenACWY-CRM Vaccination</measure>
    <time_frame>Up to 361 days after vaccination</time_frame>
    <description>Percentages of subjects with carriage of N. meningitidis serogroups ACWY in subjects at different time points of the study after administration of a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Carriage of N. Meningitidis Genogroup Y at Different Time Points After MenACWY-CRM Vaccination</measure>
    <time_frame>Up to 361 days after vaccination</time_frame>
    <description>Percentages of subjects with carriage of N. meningitidis genogroup Y in subjects at different time points of the study after administration of a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Carriage of N. Meningitidis Serogroup Y at Different Time Points After MenACWY-CRM Vaccination</measure>
    <time_frame>Up to 361 days after vaccination</time_frame>
    <description>Percentages of subjects with carriage of N. meningitidis serogroup Y in subjects at different time points of the study after administration of a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With New Acquisition of Pharyngeal Carriage of All ST Types of N. Meningitidis Genogroup B at Different Time Points Following rMenB+OMV NZ Vaccination</measure>
    <time_frame>Up to 361 days after vaccination</time_frame>
    <description>The percentages of subjects with newly acquired pharyngeal carriage of all ST types of N. meningitidis genogroup B in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With New Acquisition of Pharyngeal Carriage of Virulent ST Types of N. Meningitidis Genogroup B at Different Time Points Following rMenB+OMV NZ Vaccination</measure>
    <time_frame>Up to 361 days after vaccination</time_frame>
    <description>The percentages of subjects with newly acquired pharyngeal carriage of virulent ST types of N. meningitidis genogroup B in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With New Acquisition of Pharyngeal Carriage of All N. Meningitidis at Different Time Points Following rMenB+OMV NZ Vaccination</measure>
    <time_frame>Up to 361 days after vaccination</time_frame>
    <description>The percentages of subjects with newly acquired pharyngeal carriage of all N. meningitidis in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With New Acquisition of Pharyngeal Carriage of N. Meningitidis Genogroups ABCWY at Different Time Points Following rMenB+OMV NZ Vaccination</measure>
    <time_frame>Up to 361 days after vaccination</time_frame>
    <description>The percentages of subjects with newly acquired pharyngeal carriage of N. meningitidis genogroups ABCWY in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With New Acquisition of Pharyngeal Carriage of N. Meningitidis Serogroups ACWY at Different Time-points After MenACWY-CRM Vaccination</measure>
    <time_frame>Up to 361 days after vaccination</time_frame>
    <description>The percentages of subjects with newly acquired pharyngeal carriage of N.meningitidis serogroups A,C, W or Y at different time-points in the study after MenACWY-CRM vaccination as compared to the control group is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With New Acquisition of Pharyngeal Carriage of N. Meningitidis Serogroup Y at Different Time-points After MenACWY-CRM Vaccination</measure>
    <time_frame>Up to 361 days after vaccination</time_frame>
    <description>The percentages of subjects with newly acquired pharyngeal carriage of N.meningitidis serogroup Y at different time-points in the study after MenACWY-CRM vaccination as compared to the control group is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Duration of Any Carriage of N.Meningitidis Strains After Vaccination With rMenB+OMV</measure>
    <time_frame>Any post vaccination timepoint (the date of first observation of the carriage and the date of the last observation of the carriage)</time_frame>
    <description>The duration of carriage of any N.meningitidis strains after receiving two doses of rMenB+OMV compared to that in the control group is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Duration of Carriage of Any N. Meningitidis Strain After Vaccination With MenACWY-CRM</measure>
    <time_frame>Any time post vaccination (the date of first observation of the carriage and the date of the last observation of the carriage)</time_frame>
    <description>The duration of carriage of any N meningitidis strain after receiving one dose MenACWY-CRM as compared to that in control group is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Duration of Carriage After New Acquisition N.Meningitidis Strains Following Vaccination With rMenB+OMV Vaccine</measure>
    <time_frame>Any post vaccination timepoint (the date of first observation of the carriage and the date of the last observation of the carriage)</time_frame>
    <description>The duration of carriage after new acquisition of N.meningitidis strains after receiving two doses of rMenB+OMV vaccine compared to that in the control group is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Duration of Carriage After New Acquisition N.Meningitidis Strains Following Vaccination With MenACWY Vaccine</measure>
    <time_frame>Any post vaccination timepoint (the date of first observation of the carriage and the date of the last observation of the carriage)</time_frame>
    <description>The duration of carriage after new acquisition of N.meningitidis strains after receiving one dose of MenACWY-CRM vaccine compared to that in the control group is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With N. Meningitidis Carriage of Virulent ST of Group B, Stratified by Pre-vaccination hSBA Titer After rMenB+OMV NZ Vaccination</measure>
    <time_frame>Up to 361 days after vaccination</time_frame>
    <description>The percentages of subjects with N. meningitidis Virulent ST of serogroup B, at different time points of the study, in subjects stratified by pre-vaccination hSBA (&lt;4 and ≥4) titers after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.
The serum bactericidal antibodies directed against N.meningitides serogroups, are measured by Serum Bactericidal Assay using human complement (hSBA).
H44/76, 5/99 and NZ98/254 are strains in serogroup B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With N. Meningitidis Carriage of Serogroup Y After MenACWY-CRM Vaccination, Stratified by Pre-vaccination hSBA Titers</measure>
    <time_frame>Up to 12 months after vaccination</time_frame>
    <description>The prevalence of carriage of N. meningitidis serogroup Y, at different time points of the study, in subjects stratified by pre-vaccination hSBA (&lt;8 and ≥8) titers, after administration of one dose of MenACWY-CRM vaccine as compared to the control group is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA Titers ≥1:4 Against N. Meningitidis Serogroup B After rMenB+OMV NZ or MenACWY-CRM Vaccination Compared to Control Group</measure>
    <time_frame>Up to 361 days after vaccination</time_frame>
    <description>The percentages of subjects with hSBA titers ≥1:4 against the three strains of N. meningitidis B, after rMenB+OMV NZ or MenACWY-CRM vaccination at different time points of the study as compared to the control group are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The hSBA Geometric Mean Titers Against N. Meningitidis Serogroup B, After rMenB+OMV NZ or MenACWY-CRM Vaccination Compared to Control Group.</measure>
    <time_frame>Up to 361 days after vaccination</time_frame>
    <description>The hSBA Geometric Mean Titers (GMTs) against the three strains of N. meningitidis serogroup B, after rMenB+OMV NZ or MenACWY-CRM vaccination at different time points of the study as compared to the control group are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA Titers ≥1:8 Against N. Meningitidis Serogroup C and Y, After rMenB+OMV NZ or MenACWY-CRM Vaccination Compared to Control Group.</measure>
    <time_frame>Up to 361 days after vaccination</time_frame>
    <description>The percentages of subjects with hSBA titers ≥1:8 against N. meningitidis serogroups C and Y, after rMenB+OMV NZ or MenACWY-CRM vaccination at different time points of the study as compared to the control group are reported.
As serogroup A and W strains were not detected in substantial proportion of subjects during pharyngeal carriage analysis, these serogroups were not tested.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The hSBA Geometric Mean Titers Against N. Meningitidis Serogroup C and Y, After rMenB+OMV NZ or MenACWY-CRM Vaccination Compared to Control Group.</measure>
    <time_frame>Up to 361 days after vaccination</time_frame>
    <description>The hSBA antibody titers against N. meningitidis serogroups C and Y after rMenB+OMV NZ or MenACWY-CRM vaccination at different time points of the study as compared to the control group, are reported as GMTs.
Serogroups A and W were not analysed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA Seroresponse Against N. Meningitidis Serogroups C and Y After Vaccination With rMenB+OMV NZ or MenACWY-CRM Compared to Control Group.</measure>
    <time_frame>61 days</time_frame>
    <description>The percentages of subjects with hSBA seroresponse against N. meningitidis serogroups C and Y, after rMenB+OMV NZ or MenACWY-CRM vaccination as compared to the control group are reported.
Seroresponse to N. meningitidis serogroups Cand Y is defined as :(1)for subjects with a pre-vaccination hSBA titer &lt; 1:4 to a post-vaccination hSBA titer ≥ 1:8 or (2) for subjects with a pre-vaccination hSBA titer ≥ 1:4, an increase in hSBA titer of at least four times the pre-vaccination titer.
Analysis was not done for serogroups A and W.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The hSBA Geometric Mean Titers Against N. Meningitidis Serogroups C and Y in Subjects (Who Have Received a Prior Dose of MenC Vaccine) After Vaccination With MenACWY-CRM in This Study Compared to Control Group</measure>
    <time_frame>Up to 361 days after vaccination</time_frame>
    <description>The hSBA geometric mean titers against the N. meningitidis serogroups C and Y in subjects (who have received a prior dose of MenC vaccine) after MenACWY-CRM vaccination at different time points of the study as compared to the control group are reported.
Analysis was not done for serogroups A and W.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects (Who Have Received a Prior Dose of MenC Vaccine) With hSBA Titers ≥1:8 Against N. Meningitidis Serogroups C and Y After Vaccination With MenACWY-CRM in This Study Compared to Control Group.</measure>
    <time_frame>Up to 361 days after vaccination</time_frame>
    <description>The percentages of subjects (who have received a prior dose of MenC vaccine) with hSBA titers ≥1:8 against N. meningitidis serogroups C and Y after receiving MenACWY-CRM vaccination in this study as compared to the control group are reported.
Analysis was not done for serogroups A and W.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Vaccination With rMenB+OMV NZ or MenACWY-CRM Compared to Control Group</measure>
    <time_frame>Day 1 through day 7 after any vaccination</time_frame>
    <description>The safety and tolerability of two doses of rMenB+OMV NZ vaccine (Group rMenB+OMV) and one dose of MenACWY-CRM vaccine (Group MenACWY) was assessed in terms of number of subjects with solicited local and systemic adverse events and other adverse events, following vaccination and compared to that of the control group.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2968</enrollment>
  <condition>N. Meningitidis Carriage</condition>
  <arm_group>
    <arm_group_label>rMenB+OMV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MenACWY</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects (18-24 years) received one injection of MenACWY-CRM vaccine followed by one injection of placebo, one month apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal B Recombinant + Outer Membrane Vesicle vaccine (rMenB+OMV NZ)</intervention_name>
    <arm_group_label>rMenB+OMV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY-CRM conjugate vaccine</intervention_name>
    <arm_group_label>MenACWY</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Japanese Encephalitis vaccine</intervention_name>
    <arm_group_label>Control</arm_group_label>
    <other_name>IXIARO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects, 18-24 years of age who provided written informed consent at the time
             of enrollment;

          -  Subjects who were available for all the visits scheduled in the study;

          -  Subjects who were in good health as determined by the outcome of medical history,
             physical examination and clinical judgment of the investigator.

        Exclusion Criteria:

          -  History of any serogroup B meningococcal vaccine administration;

          -  Current or previous, confirmed or suspected disease caused by N. meningitidis;

          -  Household contact with and/or intimate exposure to an individual with any laboratory
             confirmed N. meningitidis infection within 60 days of enrollment;

          -  Significant acute or chronic infection within the previous 7 days or fever (defined as
             oral temperature ≥38ºC) within the previous day;

          -  Antibiotics within 3 days (72 hours) prior to enrollment;

          -  Pregnancy or nursing (breastfeeding) mothers;

          -  Females of childbearing age who had not used or did not plan to use acceptable birth
             control measures, for the 12 months duration of the study. Oral, injected or implanted
             hormonal contraceptive, diaphragm, condom, intrauterine device or sexual abstinence
             were considered acceptable forms of birth control. If sexually active the subject must
             have been using one of the accepted birth control methods for at least 30 days prior
             to study entry;

          -  Any serious chronic or progressive disease (e.g., neoplasm, diabetes, cardiac disease,
             hepatic disease, progressive neurological disease or seizure disorder; autoimmune
             disease, human immunodeficiency virus (HIV) infection or acquired immunodeficiency
             syndrome (AIDS), or blood dyscrasias or diathesis, signs of cardiac or renal failure
             or severe malnutrition);

          -  Known or suspected impairment/alteration of the immune system, immunosuppressive
             therapy, including use of corticosteroids in immunosuppressive doses or chronic use of
             inhaled high-potency corticosteroids within the previous 60 days. [Use of topical
             corticosteroids administered during the study in limited areas (i.e., eczema on knees
             or face or elbows) of the body were allowed]; use of immunostimulants;

          -  Receipt of blood, blood products and/or plasma derivatives, or a parenteral
             immunoglobulin preparation within the previous 90 days;

          -  History of severe allergic reactions after previous vaccinations or hypersensitivity
             to any vaccine component;

          -  Participation in another clinical trial within the last 90 days or planned for during
             study;

          -  Family members and household members of research staff;

          -  Any condition which in the opinion of the investigator and/or the Regional MD may
             interfere with the evaluation of the study objectives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines and Diagnostics</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Center, University of Surrey</name>
      <address>
        <city>Surrey</city>
        <state>England</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Children's Vaccine Center, University of Bristol,</name>
      <address>
        <city>Bristol, England</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool and Broad Green University Hospital Trust</name>
      <address>
        <city>Liverpool, England</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Georges Vaccine Institute, St Georges, University of London</name>
      <address>
        <city>London, England</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Welcome Trust Clinical Research Facility, University of Manchester</name>
      <address>
        <city>Manchester, England</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The James Cook University Hospital</name>
      <address>
        <city>Middlesbrough, England</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cripps Health Centre, University Park</name>
      <address>
        <city>Nottingham, England</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oxford, Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine</name>
      <address>
        <city>Oxford, England</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Facility, Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield, England</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellcome Trust Clinical Research Facility, University of Southampton</name>
      <address>
        <city>Southampton, England</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2010</study_first_submitted>
  <study_first_submitted_qc>October 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2010</study_first_posted>
  <results_first_submitted>September 4, 2013</results_first_submitted>
  <results_first_submitted_qc>December 17, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 23, 2014</results_first_posted>
  <disposition_first_submitted>December 11, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>December 11, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 13, 2012</disposition_first_posted>
  <last_update_submitted>March 22, 2016</last_update_submitted>
  <last_update_submitted_qc>March 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningococcal vaccines</keyword>
  <keyword>Meningococcal B</keyword>
  <keyword>Meningococcal ACWY serogroups</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled from 10 sites in United Kingdom</recruitment_details>
      <pre_assignment_details>Total 2968 subjects were enrolled of which 14 subjects were not randomized and were therefore removed from the study (2 subjects withdrew consent and 11 subjects were withdrawn due to inappropriate enrollment and 1 withdrawn due to protocol violation).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>rMenB+OMV</title>
          <description>Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart</description>
        </group>
        <group group_id="P2">
          <title>MenACWY</title>
          <description>Subjects (18-24 years) received one injection of MenACWY-CRM vaccine followed by one injection of placebo, one month apart</description>
        </group>
        <group group_id="P3">
          <title>Control</title>
          <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="979"/>
                <participants group_id="P2" count="988"/>
                <participants group_id="P3" count="987"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="796"/>
                <participants group_id="P2" count="844"/>
                <participants group_id="P3" count="826"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="183"/>
                <participants group_id="P2" count="144"/>
                <participants group_id="P3" count="161"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
                <participants group_id="P2" count="98"/>
                <participants group_id="P3" count="123"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse event or death</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inappropriate enrollment</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reason</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to classify</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>rMenB+OMV</title>
          <description>Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart</description>
        </group>
        <group group_id="B2">
          <title>MenACWY</title>
          <description>Subjects (18-24 years) received one injection of MenACWY-CRM vaccine followed by one injection of placebo, one month apart</description>
        </group>
        <group group_id="B3">
          <title>Control</title>
          <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="979"/>
            <count group_id="B2" value="988"/>
            <count group_id="B3" value="987"/>
            <count group_id="B4" value="2954"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.9" spread="1.6"/>
                    <measurement group_id="B2" value="19.9" spread="1.6"/>
                    <measurement group_id="B3" value="19.8" spread="1.6"/>
                    <measurement group_id="B4" value="19.9" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="516"/>
                    <measurement group_id="B2" value="533"/>
                    <measurement group_id="B3" value="547"/>
                    <measurement group_id="B4" value="1596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="463"/>
                    <measurement group_id="B2" value="455"/>
                    <measurement group_id="B3" value="440"/>
                    <measurement group_id="B4" value="1358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentages of Subjects With Carriage of Virulent Sequence Types (ST) of Neisseria Meningitidis Group B, One Month After Completion of rMenB+OMV NZ Vaccination</title>
        <description>Percentages of subjects with carriage of virulent sequence types (ST) of Neisseria meningitidis group B, one month after completion of rMenB+OMV NZ vaccination. The carriage rate of virulent sequence types (ST) of N. meningitidis group B (genogroupable) in subjects, one month after receiving two doses of rMenB+OMV NZ, as compared to the control group, was reported.
Virulent ST types are defined as Clonal Complex multi locus sequence typing (MLST) or ST type being the same compared to history data (Clonal Complexes MLST or ST types found to be virulent and causing diseases) from the years 2006 to 2010.</description>
        <time_frame>61 days (31 days after receiving the second injection)</time_frame>
        <population>Analysis was done on the modified-intention to treat (MITT) dataset (Pharyngeal carriage), i.e subjects who actually received a study vaccination and provided at least one evaluable swab sample at baseline and after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>rMenB+OMV</title>
            <description>Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Carriage of Virulent Sequence Types (ST) of Neisseria Meningitidis Group B, One Month After Completion of rMenB+OMV NZ Vaccination</title>
          <description>Percentages of subjects with carriage of virulent sequence types (ST) of Neisseria meningitidis group B, one month after completion of rMenB+OMV NZ vaccination. The carriage rate of virulent sequence types (ST) of N. meningitidis group B (genogroupable) in subjects, one month after receiving two doses of rMenB+OMV NZ, as compared to the control group, was reported.
Virulent ST types are defined as Clonal Complex multi locus sequence typing (MLST) or ST type being the same compared to history data (Clonal Complexes MLST or ST types found to be virulent and causing diseases) from the years 2006 to 2010.</description>
          <population>Analysis was done on the modified-intention to treat (MITT) dataset (Pharyngeal carriage), i.e subjects who actually received a study vaccination and provided at least one evaluable swab sample at baseline and after vaccination.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="974"/>
                <count group_id="O2" value="984"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="6" upper_limit="10"/>
                    <measurement group_id="O2" value="7" lower_limit="6" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 (N= 916, 928)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="8" upper_limit="12"/>
                    <measurement group_id="O2" value="8" lower_limit="6" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine Group Odds Ratios for carriage of virulent ST strain of N. meningitidis group B in 4CMenB group as compared to the control group at 1 month after receiving the 2nd rMenB+OMV NZ vaccination</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3828</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.185</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.809</ci_lower_limit>
            <ci_upper_limit>1.737</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentages of Subjects With Combined Carriage of N. Meningitidis Serogroups A, C, W and Y, One Month After MenACWY-CRM Vaccination</title>
        <description>The percentage of subjects with combined carriage rate of N. meningitidis serogroups A, C, W and Y in subjects, one month after receiving a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.</description>
        <time_frame>31 days after MenACWY-CRM injection</time_frame>
        <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY</title>
            <description>Subjects (18-24 years) received one injection of MenACWY-CRM vaccine followed by one injection of placebo, one month apart</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Combined Carriage of N. Meningitidis Serogroups A, C, W and Y, One Month After MenACWY-CRM Vaccination</title>
          <description>The percentage of subjects with combined carriage rate of N. meningitidis serogroups A, C, W and Y in subjects, one month after receiving a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.</description>
          <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="981"/>
                <count group_id="O2" value="984"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="5" upper_limit="8"/>
                    <measurement group_id="O2" value="5" lower_limit="4" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1 (N=956, 947)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="5" upper_limit="8"/>
                    <measurement group_id="O2" value="6" lower_limit="5" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine Group Odds Ratios for carriage of combined N. meningitidis serogroups A, C, W, Y in the MenACWY-CRM group compared to Control group at 1 month after receiving 1 injection of MenACWY vaccine</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.840</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.555</ci_lower_limit>
            <ci_upper_limit>1.273</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Carriage of All ST Types of N. Meningitidis B (Genogroupable) at Different Time Points Following rMenB+OMV NZ Vaccination</title>
        <description>The percentage of subjects with carriage of all (virulent + non-virulent) ST types of N. meningitidis B (genogroupable) in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.</description>
        <time_frame>Up to 361 days after vaccination</time_frame>
        <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
        <group_list>
          <group group_id="O1">
            <title>rMenB+OMV</title>
            <description>Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Carriage of All ST Types of N. Meningitidis B (Genogroupable) at Different Time Points Following rMenB+OMV NZ Vaccination</title>
          <description>The percentage of subjects with carriage of all (virulent + non-virulent) ST types of N. meningitidis B (genogroupable) in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.</description>
          <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="974"/>
                <count group_id="O2" value="984"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="8" upper_limit="11"/>
                    <measurement group_id="O2" value="9" lower_limit="7" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 1st vaccination (Day 31) N=931, 947</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="7" upper_limit="11"/>
                    <measurement group_id="O2" value="9" lower_limit="7" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd vaccination (Day 61) N=916, 928</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="9" upper_limit="13"/>
                    <measurement group_id="O2" value="10" lower_limit="8" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months post 2nd vaccination (Day 121) N=860, 885</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="8" upper_limit="12"/>
                    <measurement group_id="O2" value="10" lower_limit="8" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months post 2nd vaccination (Day 181) N=832, 864</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="8" upper_limit="12"/>
                    <measurement group_id="O2" value="10" lower_limit="8" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd vaccination (Day 361) N=797,827</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="6" upper_limit="10"/>
                    <measurement group_id="O2" value="10" lower_limit="8" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Carriage of Virulent ST Types of N. Meningitidis Group B at Any Time Point After rMenB+OMV NZ Vaccination</title>
        <description>Percentage of subjects with carriage of virulent ST types of N. meningitidis group B (genogroupable) in subjects at different time points of the study point after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.</description>
        <time_frame>Up to 361 days after vaccination</time_frame>
        <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
        <group_list>
          <group group_id="O1">
            <title>rMenB+OMV</title>
            <description>Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Carriage of Virulent ST Types of N. Meningitidis Group B at Any Time Point After rMenB+OMV NZ Vaccination</title>
          <description>Percentage of subjects with carriage of virulent ST types of N. meningitidis group B (genogroupable) in subjects at different time points of the study point after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.</description>
          <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="974"/>
                <count group_id="O2" value="984"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="6" upper_limit="10"/>
                    <measurement group_id="O2" value="7" lower_limit="6" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 1st vaccination (Day 31) N=931,947</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="6" upper_limit="10"/>
                    <measurement group_id="O2" value="8" lower_limit="6" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd vaccination (Day 61) N=916, 928</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="8" upper_limit="12"/>
                    <measurement group_id="O2" value="8" lower_limit="6" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months post 2nd vaccination (Day 121) N=860, 885</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="7" upper_limit="11"/>
                    <measurement group_id="O2" value="9" lower_limit="8" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months post 2nd vaccination (Day 181) N=832,864</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="7" upper_limit="11"/>
                    <measurement group_id="O2" value="9" lower_limit="7" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd vaccination (Day 361) N=797,827</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="6" upper_limit="10"/>
                    <measurement group_id="O2" value="9" lower_limit="7" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Carriage of Nonvirulent ST Types of N. Meningitidis Group B at Any Time Point After rMenB+OMV NZ Vaccination</title>
        <description>Percentage of subjects with carriage of nonvirulent ST types of N. meningitidis group B (genogroupable) in subjects at different time points of the study point after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.</description>
        <time_frame>Up to 361 days after vaccination</time_frame>
        <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
        <group_list>
          <group group_id="O1">
            <title>rMenB+OMV</title>
            <description>Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Carriage of Nonvirulent ST Types of N. Meningitidis Group B at Any Time Point After rMenB+OMV NZ Vaccination</title>
          <description>Percentage of subjects with carriage of nonvirulent ST types of N. meningitidis group B (genogroupable) in subjects at different time points of the study point after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.</description>
          <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="974"/>
                <count group_id="O2" value="984"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="2"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 1st vaccination (N=931,947)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd vaccination (N=916,928)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="2"/>
                    <measurement group_id="O2" value="2" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months post 2nd vaccination (N=860,885)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months post 2nd vaccination (N=832,864)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd vaccination (N=797,827)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Carriage of All N.Meningitidis Strain at Different Time Points After rMenB+OMV NZ Vaccination</title>
        <description>Percentage of subjects with carriage of all N.meningitidis strains combined in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.</description>
        <time_frame>Up to 361 days after vaccination</time_frame>
        <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
        <group_list>
          <group group_id="O1">
            <title>rMenB+OMV</title>
            <description>Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Carriage of All N.Meningitidis Strain at Different Time Points After rMenB+OMV NZ Vaccination</title>
          <description>Percentage of subjects with carriage of all N.meningitidis strains combined in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.</description>
          <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="974"/>
                <count group_id="O2" value="984"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="31" upper_limit="37"/>
                    <measurement group_id="O2" value="31" lower_limit="28" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 1st vaccination (N=931, 947)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="31" upper_limit="37"/>
                    <measurement group_id="O2" value="32" lower_limit="29" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd vaccination (N=916, 928)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" lower_limit="35" upper_limit="41"/>
                    <measurement group_id="O2" value="36" lower_limit="33" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months post 2nd vaccination (N=860, 885)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="32" upper_limit="39"/>
                    <measurement group_id="O2" value="36" lower_limit="33" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months post 2nd vaccination (N=832, 864)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="30" upper_limit="37"/>
                    <measurement group_id="O2" value="36" lower_limit="33" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd vaccination (N=797, 827)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="24" upper_limit="30"/>
                    <measurement group_id="O2" value="30" lower_limit="27" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Carriage of N.Meningitidis ABCWY Genogroups at Different Time Points After rMenB+OMV NZ Vaccination</title>
        <description>Percentages of subjects with carriage of N.meningitidis ABCWY genogroups in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.</description>
        <time_frame>Up to 361 days after vaccination</time_frame>
        <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
        <group_list>
          <group group_id="O1">
            <title>rMenB+OMV</title>
            <description>Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Carriage of N.Meningitidis ABCWY Genogroups at Different Time Points After rMenB+OMV NZ Vaccination</title>
          <description>Percentages of subjects with carriage of N.meningitidis ABCWY genogroups in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.</description>
          <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="974"/>
                <count group_id="O2" value="984"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="17" upper_limit="22"/>
                    <measurement group_id="O2" value="17" lower_limit="15" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 1st vaccination (N=931, 947)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="17" upper_limit="22"/>
                    <measurement group_id="O2" value="19" lower_limit="16" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd vaccination (N=916, 928)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="19" upper_limit="25"/>
                    <measurement group_id="O2" value="22" lower_limit="19" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months post 2nd vaccination (N=860, 885)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="17" upper_limit="23"/>
                    <measurement group_id="O2" value="22" lower_limit="19" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months post 2nd vaccination (N=832, 864)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="17" upper_limit="22"/>
                    <measurement group_id="O2" value="23" lower_limit="20" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd vaccination (N=797, 827)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="12" upper_limit="17"/>
                    <measurement group_id="O2" value="18" lower_limit="15" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Carriage of N.Meningitidis ACWY Genogroups at Different Time Points After rMenB+OMV NZ Vaccination</title>
        <description>Percentages of subjects with carriage of N.meningitidis ACWY genogroups in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported</description>
        <time_frame>Up to 361 days after vaccination</time_frame>
        <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
        <group_list>
          <group group_id="O1">
            <title>rMenB+OMV</title>
            <description>Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Carriage of N.Meningitidis ACWY Genogroups at Different Time Points After rMenB+OMV NZ Vaccination</title>
          <description>Percentages of subjects with carriage of N.meningitidis ACWY genogroups in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported</description>
          <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="974"/>
                <count group_id="O2" value="984"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="8" upper_limit="12"/>
                    <measurement group_id="O2" value="8" lower_limit="7" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 1st vaccination (N=931, 947)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="9" upper_limit="13"/>
                    <measurement group_id="O2" value="10" lower_limit="8" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd vaccination (N=916, 928)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="9" upper_limit="13"/>
                    <measurement group_id="O2" value="12" lower_limit="10" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months post 2nd vaccination (N=860, 885)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="8" upper_limit="12"/>
                    <measurement group_id="O2" value="12" lower_limit="10" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months post 2nd vaccination (N=832, 864)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="8" upper_limit="12"/>
                    <measurement group_id="O2" value="13" lower_limit="11" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd vaccination (N=797, 827)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="5" upper_limit="8"/>
                    <measurement group_id="O2" value="8" lower_limit="6" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Carriage of N.Meningitidis Serogroups A,C,W or Y at Different Time Points After rMenB+OMV NZ Vaccination</title>
        <description>Percentages of subjects with carriage of N.meningitidis serogroups A,C,W or Y in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.</description>
        <time_frame>Up to 361 days after vaccination</time_frame>
        <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
        <group_list>
          <group group_id="O1">
            <title>rMenB+OMV</title>
            <description>Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Carriage of N.Meningitidis Serogroups A,C,W or Y at Different Time Points After rMenB+OMV NZ Vaccination</title>
          <description>Percentages of subjects with carriage of N.meningitidis serogroups A,C,W or Y in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.</description>
          <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="974"/>
                <count group_id="O2" value="984"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="6" upper_limit="9"/>
                    <measurement group_id="O2" value="5" lower_limit="4" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 1st vaccination (N=931, 947)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="5" upper_limit="9"/>
                    <measurement group_id="O2" value="6" lower_limit="5" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd vaccination (N=916, 928)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="5" upper_limit="9"/>
                    <measurement group_id="O2" value="8" lower_limit="6" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months post 2nd vaccination (N=860, 885)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="5" upper_limit="8"/>
                    <measurement group_id="O2" value="8" lower_limit="6" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months post 2nd vaccination (N=832, 864)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="5" upper_limit="8"/>
                    <measurement group_id="O2" value="9" lower_limit="7" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd vaccination (N=797, 827)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="4" upper_limit="7"/>
                    <measurement group_id="O2" value="5" lower_limit="3" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Carriage of N.Meningitidis Genogroup Y at Different Time Points After rMenB+OMV NZ Vaccination</title>
        <description>Percentages of subjects with carriage of N.meningitidis genogroup Y in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.</description>
        <time_frame>Up to 361 days after vaccination</time_frame>
        <population>Analysis was done on the MIIT dataset (Pharyngeal carriage)</population>
        <group_list>
          <group group_id="O1">
            <title>rMenB+OMV</title>
            <description>Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Carriage of N.Meningitidis Genogroup Y at Different Time Points After rMenB+OMV NZ Vaccination</title>
          <description>Percentages of subjects with carriage of N.meningitidis genogroup Y in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.</description>
          <population>Analysis was done on the MIIT dataset (Pharyngeal carriage)</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="974"/>
                <count group_id="O2" value="984"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="6" upper_limit="9"/>
                    <measurement group_id="O2" value="7" lower_limit="5" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 1st vaccination (N=931, 947)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="7" upper_limit="11"/>
                    <measurement group_id="O2" value="8" lower_limit="7" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd vaccination (N=916, 928)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="7" upper_limit="11"/>
                    <measurement group_id="O2" value="10" lower_limit="9" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months post 2nd vaccination (N=860, 885)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="6" upper_limit="10"/>
                    <measurement group_id="O2" value="10" lower_limit="8" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months post 2nd vaccination (N=832, 864)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="7" upper_limit="10"/>
                    <measurement group_id="O2" value="10" lower_limit="8" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd vaccination (N=797, 827)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="4" upper_limit="7"/>
                    <measurement group_id="O2" value="6" lower_limit="5" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Carriage of N.Meningitidis Serogroup Y at Different Time Points After rMenB+OMV NZ Vaccination</title>
        <description>Percentages of subjects with carriage of N.meningitidis serogroup Y in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.</description>
        <time_frame>Up to 361 days after vaccination</time_frame>
        <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
        <group_list>
          <group group_id="O1">
            <title>rMenB+OMV</title>
            <description>Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Carriage of N.Meningitidis Serogroup Y at Different Time Points After rMenB+OMV NZ Vaccination</title>
          <description>Percentages of subjects with carriage of N.meningitidis serogroup Y in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.</description>
          <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="974"/>
                <count group_id="O2" value="984"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="4" upper_limit="7"/>
                    <measurement group_id="O2" value="5" lower_limit="3" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 1st vaccination (N=931, 947)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="4" upper_limit="8"/>
                    <measurement group_id="O2" value="5" lower_limit="4" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd vaccination (N=916, 928)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="4" upper_limit="7"/>
                    <measurement group_id="O2" value="7" lower_limit="6" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months post 2nd vaccination (N=860, 885)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="4" upper_limit="7"/>
                    <measurement group_id="O2" value="7" lower_limit="5" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months post 2nd vaccination (N=832, 864)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="4" upper_limit="8"/>
                    <measurement group_id="O2" value="7" lower_limit="6" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd vaccination (N=797, 827)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3" upper_limit="6"/>
                    <measurement group_id="O2" value="4" lower_limit="3" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subject With Carriage of N. Meningitidis Genogroups ACWY at Different Time Points After MenACWY-CRM Vaccination</title>
        <description>Percentages of subject with carriage of N. meningitidis genogroups ACWY in subjects at different time points of the study after administration of a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.</description>
        <time_frame>Up to 361 days after vaccination</time_frame>
        <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY</title>
            <description>Subjects (18-24 years) received one injection of MenACWY-CRM vaccine followed by one injection of placebo, one month apart</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subject With Carriage of N. Meningitidis Genogroups ACWY at Different Time Points After MenACWY-CRM Vaccination</title>
          <description>Percentages of subject with carriage of N. meningitidis genogroups ACWY in subjects at different time points of the study after administration of a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.</description>
          <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="981"/>
                <count group_id="O2" value="984"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="7" upper_limit="11"/>
                    <measurement group_id="O2" value="8" lower_limit="7" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 1 dose (N=956, 947)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="8" upper_limit="12"/>
                    <measurement group_id="O2" value="10" lower_limit="8" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 months post 1 dose (N=929, 928)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="8" upper_limit="12"/>
                    <measurement group_id="O2" value="12" lower_limit="10" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 months post 1 dose (N=884, 885)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="8" upper_limit="12"/>
                    <measurement group_id="O2" value="12" lower_limit="10" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months post 1 dose (N=867, 864)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="9" upper_limit="13"/>
                    <measurement group_id="O2" value="13" lower_limit="11" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months post 1 dose (N=845, 827)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="6" upper_limit="10"/>
                    <measurement group_id="O2" value="8" lower_limit="6" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Carriage of N. Meningitidis Serogroups ACWY at Different Time Points After MenACWY-CRM Vaccination</title>
        <description>Percentages of subjects with carriage of N. meningitidis serogroups ACWY in subjects at different time points of the study after administration of a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.</description>
        <time_frame>Up to 361 days after vaccination</time_frame>
        <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY</title>
            <description>Subjects (18-24 years) received one injection of MenACWY-CRM vaccine followed by one injection of placebo, one month apart</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Carriage of N. Meningitidis Serogroups ACWY at Different Time Points After MenACWY-CRM Vaccination</title>
          <description>Percentages of subjects with carriage of N. meningitidis serogroups ACWY in subjects at different time points of the study after administration of a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.</description>
          <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="981"/>
                <count group_id="O2" value="984"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="5" upper_limit="8"/>
                    <measurement group_id="O2" value="5" lower_limit="4" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 1 dose (N=956, 947)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="5" upper_limit="8"/>
                    <measurement group_id="O2" value="6" lower_limit="5" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 months post 1 dose (N=929, 928)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="4" upper_limit="7"/>
                    <measurement group_id="O2" value="8" lower_limit="6" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 months post 1 dose (N=884, 885)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="5" upper_limit="8"/>
                    <measurement group_id="O2" value="8" lower_limit="6" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months post 1 dose (N=867, 864)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="5" upper_limit="8"/>
                    <measurement group_id="O2" value="9" lower_limit="7" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months post 1 dose (N=845, 827)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3" upper_limit="6"/>
                    <measurement group_id="O2" value="5" lower_limit="3" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Carriage of N. Meningitidis Genogroup Y at Different Time Points After MenACWY-CRM Vaccination</title>
        <description>Percentages of subjects with carriage of N. meningitidis genogroup Y in subjects at different time points of the study after administration of a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.</description>
        <time_frame>Up to 361 days after vaccination</time_frame>
        <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY</title>
            <description>Subjects (18-24 years) received one injection of MenACWY-CRM vaccine followed by one injection of placebo, one month apart</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Carriage of N. Meningitidis Genogroup Y at Different Time Points After MenACWY-CRM Vaccination</title>
          <description>Percentages of subjects with carriage of N. meningitidis genogroup Y in subjects at different time points of the study after administration of a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.</description>
          <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="981"/>
                <count group_id="O2" value="984"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="5" upper_limit="8"/>
                    <measurement group_id="O2" value="7" lower_limit="5" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 1 dose (N=956, 947)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="6" upper_limit="9"/>
                    <measurement group_id="O2" value="8" lower_limit="7" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 months post 1 dose (N=929, 928)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="6" upper_limit="9"/>
                    <measurement group_id="O2" value="10" lower_limit="9" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 months post 1 dose (N=884, 885)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="6" upper_limit="10"/>
                    <measurement group_id="O2" value="10" lower_limit="8" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months post 1 dose (N=867, 864)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="7" upper_limit="11"/>
                    <measurement group_id="O2" value="10" lower_limit="8" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months post 1 dose (N=845, 827)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="5" upper_limit="8"/>
                    <measurement group_id="O2" value="6" lower_limit="5" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Carriage of N. Meningitidis Serogroup Y at Different Time Points After MenACWY-CRM Vaccination</title>
        <description>Percentages of subjects with carriage of N. meningitidis serogroup Y in subjects at different time points of the study after administration of a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.</description>
        <time_frame>Up to 361 days after vaccination</time_frame>
        <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY</title>
            <description>Subjects (18-24 years) received one injection of MenACWY-CRM vaccine followed by one injection of placebo, one month apart</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Carriage of N. Meningitidis Serogroup Y at Different Time Points After MenACWY-CRM Vaccination</title>
          <description>Percentages of subjects with carriage of N. meningitidis serogroup Y in subjects at different time points of the study after administration of a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.</description>
          <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="981"/>
                <count group_id="O2" value="984"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3" upper_limit="6"/>
                    <measurement group_id="O2" value="5" lower_limit="3" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 1 dose (N=956, 947)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="4" upper_limit="6"/>
                    <measurement group_id="O2" value="5" lower_limit="4" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 months post 1 dose (N=929, 928)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3" upper_limit="5"/>
                    <measurement group_id="O2" value="7" lower_limit="6" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 months post 1 dose (N=884, 885)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="4" upper_limit="7"/>
                    <measurement group_id="O2" value="7" lower_limit="5" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months post 1 dose (N=867, 864)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="4" upper_limit="7"/>
                    <measurement group_id="O2" value="7" lower_limit="6" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months post 1 dose (N=845, 827)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3" upper_limit="5"/>
                    <measurement group_id="O2" value="4" lower_limit="3" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With New Acquisition of Pharyngeal Carriage of All ST Types of N. Meningitidis Genogroup B at Different Time Points Following rMenB+OMV NZ Vaccination</title>
        <description>The percentages of subjects with newly acquired pharyngeal carriage of all ST types of N. meningitidis genogroup B in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.</description>
        <time_frame>Up to 361 days after vaccination</time_frame>
        <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
        <group_list>
          <group group_id="O1">
            <title>rMenB+OMV</title>
            <description>Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With New Acquisition of Pharyngeal Carriage of All ST Types of N. Meningitidis Genogroup B at Different Time Points Following rMenB+OMV NZ Vaccination</title>
          <description>The percentages of subjects with newly acquired pharyngeal carriage of all ST types of N. meningitidis genogroup B in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.</description>
          <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="748"/>
                <count group_id="O2" value="786"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline non-carrier</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="87" upper_limit="92"/>
                    <measurement group_id="O2" value="91" lower_limit="89" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 1st vaccination (N=671, 715)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O2" value="4" lower_limit="2" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd vaccination (N=650, 687)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O2" value="2" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months post 2nd vaccination (N=628, 674)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="3" lower_limit="1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months post 2nd vaccination (N=623, 656)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O2" value="2" lower_limit="1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd vaccination (N=614, 642)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O2" value="3" lower_limit="2" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 3,5,11 months post 2nd vaccination (N=628,674)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="4" upper_limit="7"/>
                    <measurement group_id="O2" value="7" lower_limit="6" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With New Acquisition of Pharyngeal Carriage of Virulent ST Types of N. Meningitidis Genogroup B at Different Time Points Following rMenB+OMV NZ Vaccination</title>
        <description>The percentages of subjects with newly acquired pharyngeal carriage of virulent ST types of N. meningitidis genogroup B in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.</description>
        <time_frame>Up to 361 days after vaccination</time_frame>
        <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
        <group_list>
          <group group_id="O1">
            <title>rMenB+OMV</title>
            <description>Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With New Acquisition of Pharyngeal Carriage of Virulent ST Types of N. Meningitidis Genogroup B at Different Time Points Following rMenB+OMV NZ Vaccination</title>
          <description>The percentages of subjects with newly acquired pharyngeal carriage of virulent ST types of N. meningitidis genogroup B in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.</description>
          <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="748"/>
                <count group_id="O2" value="786"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline non-carrier</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" lower_limit="89" upper_limit="93"/>
                    <measurement group_id="O2" value="92" lower_limit="90" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 1st vaccination (N=682, 726)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O2" value="3" lower_limit="2" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd vaccination (N=659, 699)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O2" value="2" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months post 2nd vaccination (N=638, 686)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="2" lower_limit="1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months post 2nd vaccination (N=632, 670)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O2" value="2" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd vaccination (N=623, 656)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O2" value="2" lower_limit="1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 3,5, 11 months post 2nd vaccination (N=638,686)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="4" upper_limit="7"/>
                    <measurement group_id="O2" value="6" lower_limit="5" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With New Acquisition of Pharyngeal Carriage of All N. Meningitidis at Different Time Points Following rMenB+OMV NZ Vaccination</title>
        <description>The percentages of subjects with newly acquired pharyngeal carriage of all N. meningitidis in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.</description>
        <time_frame>Up to 361 days after vaccination</time_frame>
        <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
        <group_list>
          <group group_id="O1">
            <title>rMenB+OMV</title>
            <description>Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With New Acquisition of Pharyngeal Carriage of All N. Meningitidis at Different Time Points Following rMenB+OMV NZ Vaccination</title>
          <description>The percentages of subjects with newly acquired pharyngeal carriage of all N. meningitidis in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.</description>
          <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="748"/>
                <count group_id="O2" value="786"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline non-carrier</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" lower_limit="74" upper_limit="80"/>
                    <measurement group_id="O2" value="80" lower_limit="77" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 1st vaccination (N=578, 627)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="14" upper_limit="20"/>
                    <measurement group_id="O2" value="18" lower_limit="15" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd vaccination (N=479, 513)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="11" upper_limit="18"/>
                    <measurement group_id="O2" value="12" lower_limit="9" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months post 2nd vaccination (N=410, 452)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="6" upper_limit="12"/>
                    <measurement group_id="O2" value="13" lower_limit="10" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months post 2nd vaccination (N=374, 395)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="5" upper_limit="11"/>
                    <measurement group_id="O2" value="9" lower_limit="6" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd vaccination (N=344, 361)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="8" upper_limit="15"/>
                    <measurement group_id="O2" value="14" lower_limit="10" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 3,5, 11 months post 2nd vaccination (N=410,452)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="21" upper_limit="30"/>
                    <measurement group_id="O2" value="31" lower_limit="27" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With New Acquisition of Pharyngeal Carriage of N. Meningitidis Genogroups ABCWY at Different Time Points Following rMenB+OMV NZ Vaccination</title>
        <description>The percentages of subjects with newly acquired pharyngeal carriage of N. meningitidis genogroups ABCWY in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.</description>
        <time_frame>Up to 361 days after vaccination</time_frame>
        <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
        <group_list>
          <group group_id="O1">
            <title>rMenB+OMV</title>
            <description>Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With New Acquisition of Pharyngeal Carriage of N. Meningitidis Genogroups ABCWY at Different Time Points Following rMenB+OMV NZ Vaccination</title>
          <description>The percentages of subjects with newly acquired pharyngeal carriage of N. meningitidis genogroups ABCWY in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.</description>
          <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="748"/>
                <count group_id="O2" value="786"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline non-carrier</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" lower_limit="79" upper_limit="85"/>
                    <measurement group_id="O2" value="84" lower_limit="82" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 1st vaccination (N=611, 663)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="7" upper_limit="12"/>
                    <measurement group_id="O2" value="10" lower_limit="8" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd vaccination (N=553, 592)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="4" upper_limit="8"/>
                    <measurement group_id="O2" value="7" lower_limit="5" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months post 2nd vaccination (N=519, 551)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3" upper_limit="6"/>
                    <measurement group_id="O2" value="7" lower_limit="5" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months post 2nd vaccination (N=497, 515)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="3" upper_limit="7"/>
                    <measurement group_id="O2" value="5" lower_limit="3" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd vaccination (N=472, 491)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="4" upper_limit="8"/>
                    <measurement group_id="O2" value="6" lower_limit="4" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 3,5, 11 months post 2nd vaccination (N=519,551)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="11" upper_limit="18"/>
                    <measurement group_id="O2" value="17" lower_limit="14" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With New Acquisition of Pharyngeal Carriage of N. Meningitidis Serogroups ACWY at Different Time-points After MenACWY-CRM Vaccination</title>
        <description>The percentages of subjects with newly acquired pharyngeal carriage of N.meningitidis serogroups A,C, W or Y at different time-points in the study after MenACWY-CRM vaccination as compared to the control group is reported.</description>
        <time_frame>Up to 361 days after vaccination</time_frame>
        <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY</title>
            <description>Subjects (18-24 years) received one injection of MenACWY-CRM vaccine followed by one injection of placebo, one month apart</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With New Acquisition of Pharyngeal Carriage of N. Meningitidis Serogroups ACWY at Different Time-points After MenACWY-CRM Vaccination</title>
          <description>The percentages of subjects with newly acquired pharyngeal carriage of N.meningitidis serogroups A,C, W or Y at different time-points in the study after MenACWY-CRM vaccination as compared to the control group is reported.</description>
          <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="794"/>
                <count group_id="O2" value="786"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline non-carrier</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="92" upper_limit="96"/>
                    <measurement group_id="O2" value="95" lower_limit="93" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 1st vaccination (N=746, 745)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3" upper_limit="6"/>
                    <measurement group_id="O2" value="5" lower_limit="3" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd vaccination (N=712, 709)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O2" value="4" lower_limit="3" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months post 2nd vaccination (N=701, 680)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O2" value="3" lower_limit="2" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months post 2nd vaccination (N=685, 660)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O2" value="2" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd vaccination (N=666, 650)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1,3,5, 11 months post 2nd vaccination (N=712, 709)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="6" upper_limit="11"/>
                    <measurement group_id="O2" value="10" lower_limit="8" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With New Acquisition of Pharyngeal Carriage of N. Meningitidis Serogroup Y at Different Time-points After MenACWY-CRM Vaccination</title>
        <description>The percentages of subjects with newly acquired pharyngeal carriage of N.meningitidis serogroup Y at different time-points in the study after MenACWY-CRM vaccination as compared to the control group is reported.</description>
        <time_frame>Up to 361 days after vaccination</time_frame>
        <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY</title>
            <description>Subjects (18-24 years) received one injection of MenACWY-CRM vaccine followed by one injection of placebo, one month apart</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With New Acquisition of Pharyngeal Carriage of N. Meningitidis Serogroup Y at Different Time-points After MenACWY-CRM Vaccination</title>
          <description>The percentages of subjects with newly acquired pharyngeal carriage of N.meningitidis serogroup Y at different time-points in the study after MenACWY-CRM vaccination as compared to the control group is reported.</description>
          <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="794"/>
                <count group_id="O2" value="786"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline non-carrier</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="94" upper_limit="97"/>
                    <measurement group_id="O2" value="95" lower_limit="94" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 1st vaccination (N=758, 749)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O2" value="4" lower_limit="3" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd vaccination (N=730, 719)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="2"/>
                    <measurement group_id="O2" value="4" lower_limit="2" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months post 2nd vaccination (N=719, 693)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O2" value="2" lower_limit="1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months post 2nd vaccination (N=709, 678)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd vaccination (N=694, 669)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1,3,5, 11 months post 2nd vaccination (N=730, 719)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="5" upper_limit="8"/>
                    <measurement group_id="O2" value="8" lower_limit="6" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Duration of Any Carriage of N.Meningitidis Strains After Vaccination With rMenB+OMV</title>
        <description>The duration of carriage of any N.meningitidis strains after receiving two doses of rMenB+OMV compared to that in the control group is reported.</description>
        <time_frame>Any post vaccination timepoint (the date of first observation of the carriage and the date of the last observation of the carriage)</time_frame>
        <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
        <group_list>
          <group group_id="O1">
            <title>rMenB+OMV</title>
            <description>Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
          </group>
        </group_list>
        <measure>
          <title>The Duration of Any Carriage of N.Meningitidis Strains After Vaccination With rMenB+OMV</title>
          <description>The duration of carriage of any N.meningitidis strains after receiving two doses of rMenB+OMV compared to that in the control group is reported.</description>
          <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
          <units>Number of days</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="440"/>
                <count group_id="O2" value="470"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Genogroup B All STs (N=152, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127" lower_limit="92" upper_limit="162"/>
                    <measurement group_id="O2" value="146" lower_limit="112" upper_limit="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genogroup B virulent STs (N=142, 142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122" lower_limit="87" upper_limit="157"/>
                    <measurement group_id="O2" value="147" lower_limit="113" upper_limit="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All N meningitidis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193" lower_limit="176" upper_limit="210"/>
                    <measurement group_id="O2" value="202" lower_limit="185" upper_limit="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genogroups ABCWY (N=300, 323)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143" lower_limit="122" upper_limit="164"/>
                    <measurement group_id="O2" value="162" lower_limit="141" upper_limit="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroups ACWY (N=131, 142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104" lower_limit="79" upper_limit="129"/>
                    <measurement group_id="O2" value="113" lower_limit="87" upper_limit="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (N=106, 123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106" lower_limit="79" upper_limit="132"/>
                    <measurement group_id="O2" value="117" lower_limit="91" upper_limit="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Duration of Carriage of Any N. Meningitidis Strain After Vaccination With MenACWY-CRM</title>
        <description>The duration of carriage of any N meningitidis strain after receiving one dose MenACWY-CRM as compared to that in control group is reported.</description>
        <time_frame>Any time post vaccination (the date of first observation of the carriage and the date of the last observation of the carriage)</time_frame>
        <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY</title>
            <description>Subjects (18-24 years) received one injection of MenACWY-CRM vaccine followed by one injection of placebo, one month apart</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
          </group>
        </group_list>
        <measure>
          <title>The Duration of Carriage of Any N. Meningitidis Strain After Vaccination With MenACWY-CRM</title>
          <description>The duration of carriage of any N meningitidis strain after receiving one dose MenACWY-CRM as compared to that in control group is reported.</description>
          <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
          <units>Number of days</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroups ACWY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="62" upper_limit="114"/>
                    <measurement group_id="O2" value="113" lower_limit="87" upper_limit="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (N=110, 123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="59" upper_limit="114"/>
                    <measurement group_id="O2" value="117" lower_limit="91" upper_limit="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Duration of Carriage After New Acquisition N.Meningitidis Strains Following Vaccination With rMenB+OMV Vaccine</title>
        <description>The duration of carriage after new acquisition of N.meningitidis strains after receiving two doses of rMenB+OMV vaccine compared to that in the control group is reported.</description>
        <time_frame>Any post vaccination timepoint (the date of first observation of the carriage and the date of the last observation of the carriage)</time_frame>
        <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
        <group_list>
          <group group_id="O1">
            <title>rMenB+OMV</title>
            <description>Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
          </group>
        </group_list>
        <measure>
          <title>The Duration of Carriage After New Acquisition N.Meningitidis Strains Following Vaccination With rMenB+OMV Vaccine</title>
          <description>The duration of carriage after new acquisition of N.meningitidis strains after receiving two doses of rMenB+OMV vaccine compared to that in the control group is reported.</description>
          <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
          <units>Number of days</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="271"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Genogroup B All STs (N=76, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" lower_limit="44" upper_limit="120"/>
                    <measurement group_id="O2" value="107" lower_limit="71" upper_limit="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genogroup B virulent STs (N=77, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="42" upper_limit="117"/>
                    <measurement group_id="O2" value="107" lower_limit="70" upper_limit="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All N meningitidis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158" lower_limit="135" upper_limit="181"/>
                    <measurement group_id="O2" value="165" lower_limit="142" upper_limit="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genogroups ABCWY (N=165, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121" lower_limit="96" upper_limit="146"/>
                    <measurement group_id="O2" value="146" lower_limit="122" upper_limit="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroups ACWY (N=75, 102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111" lower_limit="79" upper_limit="143"/>
                    <measurement group_id="O2" value="120" lower_limit="89" upper_limit="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (N=61, 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111" lower_limit="76" upper_limit="146"/>
                    <measurement group_id="O2" value="120" lower_limit="87" upper_limit="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Duration of Carriage After New Acquisition N.Meningitidis Strains Following Vaccination With MenACWY Vaccine</title>
        <description>The duration of carriage after new acquisition of N.meningitidis strains after receiving one dose of MenACWY-CRM vaccine compared to that in the control group is reported.</description>
        <time_frame>Any post vaccination timepoint (the date of first observation of the carriage and the date of the last observation of the carriage)</time_frame>
        <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY</title>
            <description>Subjects (18-24 years) received one injection of MenACWY-CRM vaccine followed by one injection of placebo, one month apart</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
          </group>
        </group_list>
        <measure>
          <title>The Duration of Carriage After New Acquisition N.Meningitidis Strains Following Vaccination With MenACWY Vaccine</title>
          <description>The duration of carriage after new acquisition of N.meningitidis strains after receiving one dose of MenACWY-CRM vaccine compared to that in the control group is reported.</description>
          <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
          <units>Number of days</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroups ACWY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="57" upper_limit="123"/>
                    <measurement group_id="O2" value="120" lower_limit="89" upper_limit="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (N=74, 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="52" upper_limit="122"/>
                    <measurement group_id="O2" value="120" lower_limit="87" upper_limit="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With N. Meningitidis Carriage of Virulent ST of Group B, Stratified by Pre-vaccination hSBA Titer After rMenB+OMV NZ Vaccination</title>
        <description>The percentages of subjects with N. meningitidis Virulent ST of serogroup B, at different time points of the study, in subjects stratified by pre-vaccination hSBA (&lt;4 and ≥4) titers after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.
The serum bactericidal antibodies directed against N.meningitides serogroups, are measured by Serum Bactericidal Assay using human complement (hSBA).
H44/76, 5/99 and NZ98/254 are strains in serogroup B.</description>
        <time_frame>Up to 361 days after vaccination</time_frame>
        <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
        <group_list>
          <group group_id="O1">
            <title>rMenB+OMV</title>
            <description>Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With N. Meningitidis Carriage of Virulent ST of Group B, Stratified by Pre-vaccination hSBA Titer After rMenB+OMV NZ Vaccination</title>
          <description>The percentages of subjects with N. meningitidis Virulent ST of serogroup B, at different time points of the study, in subjects stratified by pre-vaccination hSBA (&lt;4 and ≥4) titers after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.
The serum bactericidal antibodies directed against N.meningitides serogroups, are measured by Serum Bactericidal Assay using human complement (hSBA).
H44/76, 5/99 and NZ98/254 are strains in serogroup B.</description>
          <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
          <units>Percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline hSBA &lt; 4 (H44/76) (N=60,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="6"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1month post 1st dose; hSBA&lt;4(H44/76) (N=60, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0" upper_limit="12"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1month post 2nd dose; hSBA&lt;4(H44/76) (N=60, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="2" upper_limit="16"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3months post 2nd dose; hSBA&lt;4(H44/76) (N=56, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="0" upper_limit="12"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months post 2nd dose; hSBA &lt;4(H44/76) (N=56, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="2" upper_limit="17"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd dose;hSBA &lt;4(H44/76) (N=56, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="4" upper_limit="22"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline hSBA ≥4 (H44/76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="5" upper_limit="16"/>
                    <measurement group_id="O2" value="6" lower_limit="1" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1month post 1st dose; hSBA ≥4 (H44/76) (N=130, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="2" upper_limit="11"/>
                    <measurement group_id="O2" value="10" lower_limit="2" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd dose;hSBA ≥4 (H44/76) (N=130, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="4" upper_limit="14"/>
                    <measurement group_id="O2" value="7" lower_limit="1" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months post 2nd dose;hSBA ≥4 (H44/76) (N=120,29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="5" upper_limit="16"/>
                    <measurement group_id="O2" value="14" lower_limit="4" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months post 2nd dose;hSBA ≥4 (H44/76) (N=115,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="2" upper_limit="11"/>
                    <measurement group_id="O2" value="11" lower_limit="2" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd dose;hSBA ≥4 (H44/76)(N=123,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="2" upper_limit="10"/>
                    <measurement group_id="O2" value="7" lower_limit="1" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline hSBA &lt; 4 (5/99) (N=77, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="1" upper_limit="13"/>
                    <measurement group_id="O2" value="9" lower_limit="1" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1month post 1st dose; hSBA&lt;4 (5/99) (N=77, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="1" upper_limit="11"/>
                    <measurement group_id="O2" value="9" lower_limit="1" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd dose;hSBA &lt;4 (5/99) (N=77, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="2" upper_limit="15"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months post 2nd dose;hSBA &lt;4 (5/99) (N=71, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="1" upper_limit="12"/>
                    <measurement group_id="O2" value="10" lower_limit="1" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months post 2nd dose;hSBA &lt;4 (5/99) (N=68, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O2" value="10" lower_limit="1" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd dose;hSBA &lt;4(5/99) (N=71, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="2" upper_limit="16"/>
                    <measurement group_id="O2" value="5" lower_limit="0" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline hSBA ≥4 (5/99) (N=116, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="4" upper_limit="14"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1month post 1st dose; hSBA ≥4 (5/99) (N=113, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="2" upper_limit="11"/>
                    <measurement group_id="O2" value="4" lower_limit="0.097" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd dose;hSBA ≥4 (5/99) (N=113, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="4" upper_limit="15"/>
                    <measurement group_id="O2" value="8" lower_limit="1" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months post 2nd dose;hSBA ≥4 (5/99) (N=105, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="5" upper_limit="17"/>
                    <measurement group_id="O2" value="8" lower_limit="1" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months post 2nd dose;hSBA ≥4 (5/99) (N=103, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="3" upper_limit="15"/>
                    <measurement group_id="O2" value="4" lower_limit="0" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd dose;hSBA ≥4(5/99) (N=108, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="3" upper_limit="13"/>
                    <measurement group_id="O2" value="4" lower_limit="0.097" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline hSBA &lt; 4 (NZ98/254) (N=83, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="8"/>
                    <measurement group_id="O2" value="6" lower_limit="1" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1month post 1st dose; hSBA&lt;4(NZ98/254) (N=81, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="1" upper_limit="10"/>
                    <measurement group_id="O2" value="7" lower_limit="1" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1month post 2nd dose; hSBA&lt;4 (NZ98/254) (N=81, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="1" upper_limit="10"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months post 2nd dose;hSBA &lt;4 (NZ98/254)(N=75,29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="3" lower_limit="0.087" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months post 2nd dose;hSBA &lt;4 (NZ98/254)(N=70,29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O2" value="3" lower_limit="0.087" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd dose;hSBA &lt;4(NZ98/254)(N=75,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="5" upper_limit="20"/>
                    <measurement group_id="O2" value="4" lower_limit="0.09" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline hSBA ≥4 (NZ98/254) (N=110, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="5" upper_limit="17"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1month post 1st dose; hSBA ≥4 (NZ98/254)(N=109,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="2" upper_limit="12"/>
                    <measurement group_id="O2" value="6" lower_limit="0" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd dose;hSBA ≥4 (NZ98/254)(N=109,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="5" upper_limit="17"/>
                    <measurement group_id="O2" value="11" lower_limit="1" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months post 2nd dose;hSBA ≥4(NZ98/254)(N=101,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="6" upper_limit="19"/>
                    <measurement group_id="O2" value="18" lower_limit="4" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months post 2nd dose;hSBA ≥4(NZ98/254)(N=101,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="3" upper_limit="15"/>
                    <measurement group_id="O2" value="13" lower_limit="2" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd dose;hSBA≥4(NZ98/254)(N=104,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="1" upper_limit="10"/>
                    <measurement group_id="O2" value="6" lower_limit="0" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With N. Meningitidis Carriage of Serogroup Y After MenACWY-CRM Vaccination, Stratified by Pre-vaccination hSBA Titers</title>
        <description>The prevalence of carriage of N. meningitidis serogroup Y, at different time points of the study, in subjects stratified by pre-vaccination hSBA (&lt;8 and ≥8) titers, after administration of one dose of MenACWY-CRM vaccine as compared to the control group is reported.</description>
        <time_frame>Up to 12 months after vaccination</time_frame>
        <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY</title>
            <description>Subjects (18-24 years) received one injection of MenACWY-CRM vaccine followed by one injection of placebo, one month apart</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With N. Meningitidis Carriage of Serogroup Y After MenACWY-CRM Vaccination, Stratified by Pre-vaccination hSBA Titers</title>
          <description>The prevalence of carriage of N. meningitidis serogroup Y, at different time points of the study, in subjects stratified by pre-vaccination hSBA (&lt;8 and ≥8) titers, after administration of one dose of MenACWY-CRM vaccine as compared to the control group is reported.</description>
          <population>Analysis was done on the MITT dataset (Pharyngeal carriage)</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline hSBA &lt;8 (MenY) (N=42, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="8"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1month post 1st dose; hSBA &lt;8 (MenY) (N=39, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="3" lower_limit="0.063" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd dose;hSBA &lt;8 (MenY) (N=39, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months post 2nd dose;hSBA &lt;8 (MenY) (N=36, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O2" value="3" lower_limit="0.068" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months post 2nd dose;hSBA &lt;8 (MenY) (N=36, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O2" value="6" lower_limit="1" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd dose;hSBA &lt;8 (MenY) (N=34, 35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0.074" upper_limit="15"/>
                    <measurement group_id="O2" value="6" lower_limit="1" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline hSBA ≥8 (MenY)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="3" upper_limit="11"/>
                    <measurement group_id="O2" value="6" lower_limit="3" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1month post 1st dose; hSBA ≥8 (MenY) (N=146,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="3" upper_limit="11"/>
                    <measurement group_id="O2" value="5" lower_limit="2" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd dose;hSBA ≥8 (MenY) (N=143, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="2" upper_limit="10"/>
                    <measurement group_id="O2" value="5" lower_limit="2" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months post 2nd dose;hSBA ≥8 (MenY) (N=131, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="4" upper_limit="14"/>
                    <measurement group_id="O2" value="7" lower_limit="4" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months post 2nd dose;hSBA ≥8 (MenY) (N=130, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="5" upper_limit="16"/>
                    <measurement group_id="O2" value="5" lower_limit="2" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd dose;hSBA ≥8 (MenY) (N=129,135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="1" upper_limit="9"/>
                    <measurement group_id="O2" value="3" lower_limit="1" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA Titers ≥1:4 Against N. Meningitidis Serogroup B After rMenB+OMV NZ or MenACWY-CRM Vaccination Compared to Control Group</title>
        <description>The percentages of subjects with hSBA titers ≥1:4 against the three strains of N. meningitidis B, after rMenB+OMV NZ or MenACWY-CRM vaccination at different time points of the study as compared to the control group are reported.</description>
        <time_frame>Up to 361 days after vaccination</time_frame>
        <population>Analysis was done on the MITT dataset (Immunogenicity subset) i.e all enrolled subjects who actually received a study vaccination, provided at least one evaluable serum sample after vaccination and whose assay result was available for at least one serogroup.</population>
        <group_list>
          <group group_id="O1">
            <title>rMenB+OMV</title>
            <description>Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart</description>
          </group>
          <group group_id="O2">
            <title>MenACWY</title>
            <description>Subjects (18-24 years) received one injection of MenACWY-CRM vaccine followed by one injection of placebo, one month apart</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With hSBA Titers ≥1:4 Against N. Meningitidis Serogroup B After rMenB+OMV NZ or MenACWY-CRM Vaccination Compared to Control Group</title>
          <description>The percentages of subjects with hSBA titers ≥1:4 against the three strains of N. meningitidis B, after rMenB+OMV NZ or MenACWY-CRM vaccination at different time points of the study as compared to the control group are reported.</description>
          <population>Analysis was done on the MITT dataset (Immunogenicity subset) i.e all enrolled subjects who actually received a study vaccination, provided at least one evaluable serum sample after vaccination and whose assay result was available for at least one serogroup.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline H44/76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" lower_limit="62" upper_limit="75"/>
                    <measurement group_id="O2" value="71" lower_limit="57" upper_limit="83"/>
                    <measurement group_id="O3" value="62" lower_limit="47" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd dose (H44/76) (N=189, 45, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="76" lower_limit="60" upper_limit="87"/>
                    <measurement group_id="O3" value="63" lower_limit="47" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months post 2nd dose (H44/76) (N=173, 40, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="73" lower_limit="56" upper_limit="85"/>
                    <measurement group_id="O3" value="65" lower_limit="50" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months post 2nd dose (H44/76) (N=169, 43, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="74" lower_limit="59" upper_limit="86"/>
                    <measurement group_id="O3" value="67" lower_limit="51" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd dose (H44/76) (N=177, 41, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="91" upper_limit="98"/>
                    <measurement group_id="O2" value="76" lower_limit="60" upper_limit="88"/>
                    <measurement group_id="O3" value="70" lower_limit="54" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline 5/99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="53" upper_limit="67"/>
                    <measurement group_id="O2" value="45" lower_limit="31" upper_limit="60"/>
                    <measurement group_id="O3" value="54" lower_limit="39" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd dose (5/99) (N=189, 45, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="40" lower_limit="26" upper_limit="56"/>
                    <measurement group_id="O3" value="58" lower_limit="43" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months post 2nd dose (5/99) (N=173, 40, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="49" lower_limit="33" upper_limit="65"/>
                    <measurement group_id="O3" value="53" lower_limit="38" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months post 2nd dose (5/99) (N=169, 43, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="49" lower_limit="33" upper_limit="65"/>
                    <measurement group_id="O3" value="53" lower_limit="38" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd dose (5/99) (N=177, 41, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="94" upper_limit="99"/>
                    <measurement group_id="O2" value="51" lower_limit="35" upper_limit="67"/>
                    <measurement group_id="O3" value="63" lower_limit="48" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline NZ98/254</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" lower_limit="50" upper_limit="64"/>
                    <measurement group_id="O2" value="53" lower_limit="38" upper_limit="67"/>
                    <measurement group_id="O3" value="38" lower_limit="25" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd dose (NZ98/254) (N=189, 45, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="53" lower_limit="38" upper_limit="68"/>
                    <measurement group_id="O3" value="44" lower_limit="29" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months post 2nd dose (NZ98/254) (N=173, 40, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="88" upper_limit="96"/>
                    <measurement group_id="O2" value="48" lower_limit="32" upper_limit="64"/>
                    <measurement group_id="O3" value="48" lower_limit="33" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months post 2nd dose (NZ98/254) (N=169, 43, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" lower_limit="85" upper_limit="94"/>
                    <measurement group_id="O2" value="58" lower_limit="42" upper_limit="73"/>
                    <measurement group_id="O3" value="42" lower_limit="28" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd dose (NZ98/254) (N=177, 41, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="79" upper_limit="90"/>
                    <measurement group_id="O2" value="66" lower_limit="49" upper_limit="80"/>
                    <measurement group_id="O3" value="43" lower_limit="29" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The hSBA Geometric Mean Titers Against N. Meningitidis Serogroup B, After rMenB+OMV NZ or MenACWY-CRM Vaccination Compared to Control Group.</title>
        <description>The hSBA Geometric Mean Titers (GMTs) against the three strains of N. meningitidis serogroup B, after rMenB+OMV NZ or MenACWY-CRM vaccination at different time points of the study as compared to the control group are reported.</description>
        <time_frame>Up to 361 days after vaccination</time_frame>
        <population>Analysis was done on the MITT dataset (Immunogenicity subset)</population>
        <group_list>
          <group group_id="O1">
            <title>rMenB+OMV</title>
            <description>Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart</description>
          </group>
          <group group_id="O2">
            <title>MenACWY</title>
            <description>Subjects (18-24 years) received one injection of MenACWY-CRM vaccine followed by one injection of placebo, one month apart</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
          </group>
        </group_list>
        <measure>
          <title>The hSBA Geometric Mean Titers Against N. Meningitidis Serogroup B, After rMenB+OMV NZ or MenACWY-CRM Vaccination Compared to Control Group.</title>
          <description>The hSBA Geometric Mean Titers (GMTs) against the three strains of N. meningitidis serogroup B, after rMenB+OMV NZ or MenACWY-CRM vaccination at different time points of the study as compared to the control group are reported.</description>
          <population>Analysis was done on the MITT dataset (Immunogenicity subset)</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline H44/76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="8.74" upper_limit="14"/>
                    <measurement group_id="O2" value="11" lower_limit="6.59" upper_limit="18"/>
                    <measurement group_id="O3" value="9.42" lower_limit="5.73" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd dose (H44/76) (N=189, 45, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229" lower_limit="192" upper_limit="274"/>
                    <measurement group_id="O2" value="11" lower_limit="7.92" upper_limit="16"/>
                    <measurement group_id="O3" value="10" lower_limit="7.18" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months post 2nd dose (H44/76) (N=173, 40, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144" lower_limit="116" upper_limit="178"/>
                    <measurement group_id="O2" value="9.07" lower_limit="5.79" upper_limit="14"/>
                    <measurement group_id="O3" value="11" lower_limit="7.07" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months post 2nd dose (H44/76) (N=169, 43, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111" lower_limit="89" upper_limit="138"/>
                    <measurement group_id="O2" value="12" lower_limit="7.57" upper_limit="18"/>
                    <measurement group_id="O3" value="12" lower_limit="7.62" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd dose (H44/76) (N=177, 40, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68" lower_limit="54" upper_limit="84"/>
                    <measurement group_id="O2" value="14" lower_limit="8.84" upper_limit="22"/>
                    <measurement group_id="O3" value="14" lower_limit="8.97" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline 5/99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.44" lower_limit="5.1" upper_limit="8.13"/>
                    <measurement group_id="O2" value="3.12" lower_limit="1.97" upper_limit="4.95"/>
                    <measurement group_id="O3" value="5.49" lower_limit="3.47" upper_limit="8.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd dose (5/99) (N=189, 45, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="424" lower_limit="355" upper_limit="507"/>
                    <measurement group_id="O2" value="2.63" lower_limit="1.83" upper_limit="3.79"/>
                    <measurement group_id="O3" value="5.62" lower_limit="3.95" upper_limit="8.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months post 2nd dose (5/99) (N=173, 40, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169" lower_limit="139" upper_limit="207"/>
                    <measurement group_id="O2" value="2.95" lower_limit="1.94" upper_limit="4.47"/>
                    <measurement group_id="O3" value="5.6" lower_limit="3.8" upper_limit="8.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months post 2nd dose (5/99) (N=169, 43, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105" lower_limit="87" upper_limit="128"/>
                    <measurement group_id="O2" value="3.36" lower_limit="2.27" upper_limit="4.97"/>
                    <measurement group_id="O3" value="5.32" lower_limit="3.63" upper_limit="7.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd dose (5/99) (N=177, 41, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" lower_limit="45" upper_limit="67"/>
                    <measurement group_id="O2" value="3.58" lower_limit="2.37" upper_limit="5.4"/>
                    <measurement group_id="O3" value="5.98" lower_limit="4.05" upper_limit="8.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline NZ98/254</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.15" lower_limit="4.82" upper_limit="7.84"/>
                    <measurement group_id="O2" value="4.32" lower_limit="2.66" upper_limit="7"/>
                    <measurement group_id="O3" value="4.16" lower_limit="2.58" upper_limit="6.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd dose (NZ98/254) (N=188, 45, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="80" upper_limit="122"/>
                    <measurement group_id="O2" value="4.82" lower_limit="3.11" upper_limit="7.47"/>
                    <measurement group_id="O3" value="3.88" lower_limit="2.54" upper_limit="5.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months post 2nd dose (NZ98/254) (N=172, 40, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="44" upper_limit="73"/>
                    <measurement group_id="O2" value="4.93" lower_limit="2.89" upper_limit="8.4"/>
                    <measurement group_id="O3" value="4.72" lower_limit="2.87" upper_limit="7.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months post 2nd dose (NZ98/254) (N=169, 43, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="38" upper_limit="66"/>
                    <measurement group_id="O2" value="6.5" lower_limit="3.73" upper_limit="11"/>
                    <measurement group_id="O3" value="4.67" lower_limit="2.72" upper_limit="8.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd dose (NZ98/254) (N=176, 41, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="26" upper_limit="45"/>
                    <measurement group_id="O2" value="7.77" lower_limit="4.38" upper_limit="14"/>
                    <measurement group_id="O3" value="6.93" lower_limit="3.99" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA Titers ≥1:8 Against N. Meningitidis Serogroup C and Y, After rMenB+OMV NZ or MenACWY-CRM Vaccination Compared to Control Group.</title>
        <description>The percentages of subjects with hSBA titers ≥1:8 against N. meningitidis serogroups C and Y, after rMenB+OMV NZ or MenACWY-CRM vaccination at different time points of the study as compared to the control group are reported.
As serogroup A and W strains were not detected in substantial proportion of subjects during pharyngeal carriage analysis, these serogroups were not tested.</description>
        <time_frame>Up to 361 days after vaccination</time_frame>
        <population>Analysis was done on the MITT dataset (Immunogenicity subset)</population>
        <group_list>
          <group group_id="O1">
            <title>rMenB+OMV</title>
            <description>Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart</description>
          </group>
          <group group_id="O2">
            <title>MenACWY</title>
            <description>Subjects (18-24 years) received one injection of MenACWY-CRM vaccine followed by one injection of placebo, one month apart</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With hSBA Titers ≥1:8 Against N. Meningitidis Serogroup C and Y, After rMenB+OMV NZ or MenACWY-CRM Vaccination Compared to Control Group.</title>
          <description>The percentages of subjects with hSBA titers ≥1:8 against N. meningitidis serogroups C and Y, after rMenB+OMV NZ or MenACWY-CRM vaccination at different time points of the study as compared to the control group are reported.
As serogroup A and W strains were not detected in substantial proportion of subjects during pharyngeal carriage analysis, these serogroups were not tested.</description>
          <population>Analysis was done on the MITT dataset (Immunogenicity subset)</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="194"/>
                <count group_id="O3" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Men C (N= 49, 194,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="78" upper_limit="97"/>
                    <measurement group_id="O2" value="87" lower_limit="81" upper_limit="91"/>
                    <measurement group_id="O3" value="80" lower_limit="66" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd dose (Men C) (N=48, 182, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="89" upper_limit="100"/>
                    <measurement group_id="O2" value="99" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O3" value="88" lower_limit="75" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd dose (Men C) (N=48, 158, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="83" upper_limit="99"/>
                    <measurement group_id="O2" value="97" lower_limit="93" upper_limit="99"/>
                    <measurement group_id="O3" value="88" lower_limit="74" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Men Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" lower_limit="65" upper_limit="78"/>
                    <measurement group_id="O2" value="78" lower_limit="72" upper_limit="84"/>
                    <measurement group_id="O3" value="78" lower_limit="71" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd dose (Men Y) (N=187, 182, 188)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="74" upper_limit="86"/>
                    <measurement group_id="O2" value="95" lower_limit="90" upper_limit="97"/>
                    <measurement group_id="O3" value="82" lower_limit="76" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months post 2nd dose (Men Y) (N=173,164,175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="72" upper_limit="85"/>
                    <measurement group_id="O2" value="95" lower_limit="90" upper_limit="97"/>
                    <measurement group_id="O3" value="82" lower_limit="75" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months post 2nd dose (Men Y) (N=170, 165, 170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="71" upper_limit="84"/>
                    <measurement group_id="O2" value="92" lower_limit="87" upper_limit="96"/>
                    <measurement group_id="O3" value="84" lower_limit="77" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd dose (Men Y) (N=177, 158, 165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" lower_limit="71" upper_limit="83"/>
                    <measurement group_id="O2" value="91" lower_limit="86" upper_limit="95"/>
                    <measurement group_id="O3" value="81" lower_limit="74" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The hSBA Geometric Mean Titers Against N. Meningitidis Serogroup C and Y, After rMenB+OMV NZ or MenACWY-CRM Vaccination Compared to Control Group.</title>
        <description>The hSBA antibody titers against N. meningitidis serogroups C and Y after rMenB+OMV NZ or MenACWY-CRM vaccination at different time points of the study as compared to the control group, are reported as GMTs.
Serogroups A and W were not analysed.</description>
        <time_frame>Up to 361 days after vaccination</time_frame>
        <population>Analysis was done on the MITT dataset (Immunogenicity subset)</population>
        <group_list>
          <group group_id="O1">
            <title>rMenB+OMV</title>
            <description>Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart</description>
          </group>
          <group group_id="O2">
            <title>MenACWY</title>
            <description>Subjects (18-24 years) received one injection of MenACWY-CRM vaccine followed by one injection of placebo, one month apart</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
          </group>
        </group_list>
        <measure>
          <title>The hSBA Geometric Mean Titers Against N. Meningitidis Serogroup C and Y, After rMenB+OMV NZ or MenACWY-CRM Vaccination Compared to Control Group.</title>
          <description>The hSBA antibody titers against N. meningitidis serogroups C and Y after rMenB+OMV NZ or MenACWY-CRM vaccination at different time points of the study as compared to the control group, are reported as GMTs.
Serogroups A and W were not analysed.</description>
          <population>Analysis was done on the MITT dataset (Immunogenicity subset)</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="194"/>
                <count group_id="O3" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Men C (N=49, 194, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" lower_limit="26" upper_limit="70"/>
                    <measurement group_id="O2" value="50" lower_limit="39" upper_limit="65"/>
                    <measurement group_id="O3" value="32" lower_limit="20" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd dose (Men C) (N=48, 182, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="55" upper_limit="126"/>
                    <measurement group_id="O2" value="1302" lower_limit="1050" upper_limit="1615"/>
                    <measurement group_id="O3" value="37" lower_limit="24" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd dose (MenC) (N=48, 158, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" lower_limit="38" upper_limit="91"/>
                    <measurement group_id="O2" value="438" lower_limit="343" upper_limit="560"/>
                    <measurement group_id="O3" value="41" lower_limit="25" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Men Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="14" upper_limit="22"/>
                    <measurement group_id="O2" value="19" lower_limit="15" upper_limit="23"/>
                    <measurement group_id="O3" value="19" lower_limit="15" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd dose (Men Y) (N=187, 182, 188)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="21" upper_limit="32"/>
                    <measurement group_id="O2" value="83" lower_limit="67" upper_limit="103"/>
                    <measurement group_id="O3" value="23" lower_limit="18" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months post 2nd dose (Men Y) (N=173, 164, 175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="19" upper_limit="30"/>
                    <measurement group_id="O2" value="69" lower_limit="56" upper_limit="86"/>
                    <measurement group_id="O3" value="22" lower_limit="17" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months post 2nd dose (Men Y (N=170, 165, 170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="19" upper_limit="29"/>
                    <measurement group_id="O2" value="63" lower_limit="51" upper_limit="78"/>
                    <measurement group_id="O3" value="22" lower_limit="18" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd dose (Men Y) (N=177, 158, 165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="17" upper_limit="26"/>
                    <measurement group_id="O2" value="49" lower_limit="39" upper_limit="61"/>
                    <measurement group_id="O3" value="22" lower_limit="17" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA Seroresponse Against N. Meningitidis Serogroups C and Y After Vaccination With rMenB+OMV NZ or MenACWY-CRM Compared to Control Group.</title>
        <description>The percentages of subjects with hSBA seroresponse against N. meningitidis serogroups C and Y, after rMenB+OMV NZ or MenACWY-CRM vaccination as compared to the control group are reported.
Seroresponse to N. meningitidis serogroups Cand Y is defined as :(1)for subjects with a pre-vaccination hSBA titer &lt; 1:4 to a post-vaccination hSBA titer ≥ 1:8 or (2) for subjects with a pre-vaccination hSBA titer ≥ 1:4, an increase in hSBA titer of at least four times the pre-vaccination titer.
Analysis was not done for serogroups A and W.</description>
        <time_frame>61 days</time_frame>
        <population>Analysis was done on the MITT dataset (Immunogenicity subset)</population>
        <group_list>
          <group group_id="O1">
            <title>rMenB+OMV</title>
            <description>Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart</description>
          </group>
          <group group_id="O2">
            <title>MenACWY</title>
            <description>Subjects (18-24 years) received one injection of MenACWY-CRM vaccine followed by one injection of placebo, one month apart</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With hSBA Seroresponse Against N. Meningitidis Serogroups C and Y After Vaccination With rMenB+OMV NZ or MenACWY-CRM Compared to Control Group.</title>
          <description>The percentages of subjects with hSBA seroresponse against N. meningitidis serogroups C and Y, after rMenB+OMV NZ or MenACWY-CRM vaccination as compared to the control group are reported.
Seroresponse to N. meningitidis serogroups Cand Y is defined as :(1)for subjects with a pre-vaccination hSBA titer &lt; 1:4 to a post-vaccination hSBA titer ≥ 1:8 or (2) for subjects with a pre-vaccination hSBA titer ≥ 1:4, an increase in hSBA titer of at least four times the pre-vaccination titer.
Analysis was not done for serogroups A and W.</description>
          <population>Analysis was done on the MITT dataset (Immunogenicity subset)</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="181"/>
                <count group_id="O3" value="188"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 month post 2nd dose from day 1(Men C)N=48,181,48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="2" upper_limit="20"/>
                    <measurement group_id="O2" value="81" lower_limit="75" upper_limit="87"/>
                    <measurement group_id="O3" value="4" lower_limit="1" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd dose from day 1(Men Y)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="8" upper_limit="17"/>
                    <measurement group_id="O2" value="44" lower_limit="37" upper_limit="52"/>
                    <measurement group_id="O3" value="7" lower_limit="4" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The hSBA Geometric Mean Titers Against N. Meningitidis Serogroups C and Y in Subjects (Who Have Received a Prior Dose of MenC Vaccine) After Vaccination With MenACWY-CRM in This Study Compared to Control Group</title>
        <description>The hSBA geometric mean titers against the N. meningitidis serogroups C and Y in subjects (who have received a prior dose of MenC vaccine) after MenACWY-CRM vaccination at different time points of the study as compared to the control group are reported.
Analysis was not done for serogroups A and W.</description>
        <time_frame>Up to 361 days after vaccination</time_frame>
        <population>Analysis was done on the MITT dataset (Immunogenicity subset)</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY</title>
            <description>Subjects (18-24 years) received one injection of MenACWY-CRM vaccine followed by one injection of placebo, one month apart</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart.</description>
          </group>
        </group_list>
        <measure>
          <title>The hSBA Geometric Mean Titers Against N. Meningitidis Serogroups C and Y in Subjects (Who Have Received a Prior Dose of MenC Vaccine) After Vaccination With MenACWY-CRM in This Study Compared to Control Group</title>
          <description>The hSBA geometric mean titers against the N. meningitidis serogroups C and Y in subjects (who have received a prior dose of MenC vaccine) after MenACWY-CRM vaccination at different time points of the study as compared to the control group are reported.
Analysis was not done for serogroups A and W.</description>
          <population>Analysis was done on the MITT dataset (Immunogenicity subset)</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Men C) (N=46, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" lower_limit="51" upper_limit="160"/>
                    <measurement group_id="O2" value="157" lower_limit="33" upper_limit="756"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd vaccination (Men C) (N=45, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1905" lower_limit="1305" upper_limit="2779"/>
                    <measurement group_id="O2" value="154" lower_limit="55" upper_limit="434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd vaccination (Men C) (N=45, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="691" lower_limit="464" upper_limit="1028"/>
                    <measurement group_id="O2" value="125" lower_limit="42" upper_limit="371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (Men Y)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="13" upper_limit="32"/>
                    <measurement group_id="O2" value="23" lower_limit="13" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd vaccination (Men Y) (N=45, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="55" upper_limit="142"/>
                    <measurement group_id="O2" value="19" lower_limit="10" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months post 2nd vaccination (Men Y) (N=42, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="41" upper_limit="110"/>
                    <measurement group_id="O2" value="20" lower_limit="11" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months post 2nd vaccination (Men Y) (N=45, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="41" upper_limit="103"/>
                    <measurement group_id="O2" value="20" lower_limit="11" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd vaccination (Men Y) (N=45, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" lower_limit="31" upper_limit="76"/>
                    <measurement group_id="O2" value="22" lower_limit="12" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects (Who Have Received a Prior Dose of MenC Vaccine) With hSBA Titers ≥1:8 Against N. Meningitidis Serogroups C and Y After Vaccination With MenACWY-CRM in This Study Compared to Control Group.</title>
        <description>The percentages of subjects (who have received a prior dose of MenC vaccine) with hSBA titers ≥1:8 against N. meningitidis serogroups C and Y after receiving MenACWY-CRM vaccination in this study as compared to the control group are reported.
Analysis was not done for serogroups A and W.</description>
        <time_frame>Up to 361 days after vaccination</time_frame>
        <population>Analysis was done on the MITT dataset (Immunogenicity subset)</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY</title>
            <description>Subjects (18-24 years) received one injection of MenACWY-CRM vaccine followed by one injection of placebo, one month apart</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects (Who Have Received a Prior Dose of MenC Vaccine) With hSBA Titers ≥1:8 Against N. Meningitidis Serogroups C and Y After Vaccination With MenACWY-CRM in This Study Compared to Control Group.</title>
          <description>The percentages of subjects (who have received a prior dose of MenC vaccine) with hSBA titers ≥1:8 against N. meningitidis serogroups C and Y after receiving MenACWY-CRM vaccination in this study as compared to the control group are reported.
Analysis was not done for serogroups A and W.</description>
          <population>Analysis was done on the MITT dataset (Immunogenicity subset)</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Men C) (N=46,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="82" upper_limit="99"/>
                    <measurement group_id="O2" value="100" lower_limit="54" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd vaccination (Men C) (N=45, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="92" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="54" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd vaccination (Men C) (N=45, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="92" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="54" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (Men Y)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="66" upper_limit="91"/>
                    <measurement group_id="O2" value="81" lower_limit="61" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 2nd vaccination (Men Y) (N=45, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="85" upper_limit="99"/>
                    <measurement group_id="O2" value="77" lower_limit="56" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months post 2nd vaccination (Men Y) (N=42, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="84" upper_limit="99"/>
                    <measurement group_id="O2" value="80" lower_limit="59" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months post 2nd vaccination (Men Y) (N=45, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="85" upper_limit="99"/>
                    <measurement group_id="O2" value="77" lower_limit="56" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months post 2nd vaccination (Men Y) (N=45, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" lower_limit="79" upper_limit="98"/>
                    <measurement group_id="O2" value="77" lower_limit="56" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Vaccination With rMenB+OMV NZ or MenACWY-CRM Compared to Control Group</title>
        <description>The safety and tolerability of two doses of rMenB+OMV NZ vaccine (Group rMenB+OMV) and one dose of MenACWY-CRM vaccine (Group MenACWY) was assessed in terms of number of subjects with solicited local and systemic adverse events and other adverse events, following vaccination and compared to that of the control group.</description>
        <time_frame>Day 1 through day 7 after any vaccination</time_frame>
        <population>Analysis was done on the Immunogenicity Subset, Safety Population i.e. all subjects in the exposed population who provided postvaccination safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>rMenB+OMV</title>
            <description>Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart</description>
          </group>
          <group group_id="O2">
            <title>MenACWY</title>
            <description>Subjects (18-24 years) received one injection of MenACWY-CRM vaccine followed by one injection of placebo, one month apart</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Vaccination With rMenB+OMV NZ or MenACWY-CRM Compared to Control Group</title>
          <description>The safety and tolerability of two doses of rMenB+OMV NZ vaccine (Group rMenB+OMV) and one dose of MenACWY-CRM vaccine (Group MenACWY) was assessed in terms of number of subjects with solicited local and systemic adverse events and other adverse events, following vaccination and compared to that of the control group.</description>
          <population>Analysis was done on the Immunogenicity Subset, Safety Population i.e. all subjects in the exposed population who provided postvaccination safety data.</population>
          <units>number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184"/>
                    <measurement group_id="O2" value="158"/>
                    <measurement group_id="O3" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain (N=190, 186,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181"/>
                    <measurement group_id="O2" value="143"/>
                    <measurement group_id="O3" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema (N=190, 186, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration (N=190, 186, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling (N=190, 186, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                    <measurement group_id="O2" value="133"/>
                    <measurement group_id="O3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia (N=190, 186, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea (N=190, 186, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (N=190, 186, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (N=190, 186, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155"/>
                    <measurement group_id="O2" value="117"/>
                    <measurement group_id="O3" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (N=190, 186, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (N=190, 186, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥38°C) (N= 190, 186,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature (≥40°C) (N= 190, 186, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyretic preventive med. used (N=190, 186, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyretic treatment med. used (N=190, 186, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited adverse events were collected from Day1 to day 7 post vaccination; unsolicited AEs were collected throughout the study period (Day 1-Day 361)</time_frame>
      <desc>The enrolled and safety set populations differ as 11 subjects (5 in rMenB+OMV, 4 in MeACWY and 2 in Control groups) did not receive the study vaccination and therefore did not have any safety data.</desc>
      <group_list>
        <group group_id="E1">
          <title>rMenB+OMV</title>
          <description>Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart</description>
        </group>
        <group group_id="E2">
          <title>MenACWY</title>
          <description>Subjects (18-24 years) received one injection of MenACWY-CRM vaccine followed by one injection of placebo, one month apart</description>
        </group>
        <group group_id="E3">
          <title>Control</title>
          <description>Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="985"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroiditis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Appendiceal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Diarrhea infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Genital abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Leptospirosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Viral rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Burns third degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Cartilage injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Multiple drug overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Traumatic liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="985"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Muscloskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="985"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Carcinoid tumor pulmonary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Ovarian germ cell cancer stage IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>IGA Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Pelvic-ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Vulval disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="985"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Appendicectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Ligament operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="985"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="200" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="186" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="172" subjects_at_risk="985"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="182" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="145" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="117" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="985"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="985"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="155" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="112" subjects_at_risk="985"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="984"/>
                <counts group_id="E3" subjects_affected="85" subjects_at_risk="985"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

